Velan Capital Investment Management’s Jasper Therapeutics JSPR Stock Holding History

Velan Capital Investment Management’s Portfolio JSPR Stock Details JSPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.34M	Hold	2,668,395	–	–	1.46%	19
2025 Q4	$4.88M	Hold	2,668,395	–	–	2.83%	10
2025 Q3	$6.21M	Buy	2,668,395 +1,234,567	+86%	+$3.74M	5.83%	7
2025 Q2	$7.96M	Hold	1,433,828	–	–	7.86%	3
2025 Q1	$6.17M	Hold	1,433,828	–	–	6.34%	7
2024 Q4	$30.7M	Hold	1,433,828	–	–	26.45%	1
2024 Q3	$27M	Sell	1,433,828 -38,076	-3%	-$758K	25.22%	1
2024 Q2	$32.5M	Hold	1,471,904	–	–	18.65%	2
2024 Q1	$42.1M	Buy	1,471,904 +350,000	+31%	+$6.22M	19.12%	2
2023 Q4	$8.55M	Hold	1,121,904	–	–	4.99%	5
2023 Q3	$7.59M	Hold	1,121,904	–	–	6.12%	3
2023 Q2	$14.8M	Hold	1,121,904	–	–	13.79%	1
2023 Q1	$19.6M	Buy	1,121,904 +800,000	+249%	+$14.8M	16.72%	1
2022 Q4	$1.37M	Hold	321,904	–	–	1.21%	17
2022 Q3	$2.24M	Hold	321,904	–	–	2.22%	12
2022 Q2	$5.48M	Hold	321,904	–	–	5.56%	6
2022 Q1	$10.2M	Hold	321,904	–	–	9.45%	4
2021 Q4	$22.9M	Buy	+321,904	New	+$30.1M	17.81%	1

Other funds holding JSPR

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

LPC

Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Velan Capital Investment Management's JSPR Position: Q1 2026 in Review

Velan Capital Investment Management held its Jasper Therapeutics (JSPR) position steady in Q1 2026 at 2,668,395 shares worth $2.34M. The position accounts for 1.46% of the portfolio, ranked #19.

Velan Capital Investment Management first reported a position in JSPR in Q4 2021 and has held it in 18 quarters since. The position peaked at $42.1M in Q1 2024. 58 funds tracked by Wall St. Rank hold JSPR as of Q1 2026.

Velan Capital Investment Management held 2,668,395 shares of Jasper Therapeutics worth $2.34M as of Q1 2026.
Velan Capital Investment Management left its Jasper Therapeutics share count unchanged in Q1 2026.
Jasper Therapeutics made up 1.46% of Velan Capital Investment Management's portfolio in Q1 2026, its #19 holding.
Velan Capital Investment Management first reported a position in Jasper Therapeutics in Q4 2021 and has held it in 18 quarters since.
Velan Capital Investment Management's Jasper Therapeutics position peaked at $42.1M in Q1 2024.
58 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q1 2026.

Based on Velan Capital Investment Management's 13F filing for Q1 2026, filed 15 May 2026.